FI841128A7 - Pyrimidinderivat, deras framstaellning och deras anvaendning. - Google Patents

Pyrimidinderivat, deras framstaellning och deras anvaendning. Download PDF

Info

Publication number
FI841128A7
FI841128A7 FI841128A FI841128A FI841128A7 FI 841128 A7 FI841128 A7 FI 841128A7 FI 841128 A FI841128 A FI 841128A FI 841128 A FI841128 A FI 841128A FI 841128 A7 FI841128 A7 FI 841128A7
Authority
FI
Finland
Prior art keywords
deras
pyrimidinder
vat
anvaendning
framstaellning och
Prior art date
Application number
FI841128A
Other languages
English (en)
Finnish (fi)
Other versions
FI841128A0 (fi
Inventor
Takao Takaya
Masayoshi Murata
Kiyotaka Ito
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838308290A external-priority patent/GB8308290D0/en
Priority claimed from GB838315542A external-priority patent/GB8315542D0/en
Priority claimed from GB838327859A external-priority patent/GB8327859D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of FI841128A0 publication Critical patent/FI841128A0/fi
Publication of FI841128A7 publication Critical patent/FI841128A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI841128A 1983-03-25 1984-03-21 Pyrimidinderivat, deras framstaellning och deras anvaendning. FI841128A7 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB838308290A GB8308290D0 (en) 1983-03-25 1983-03-25 Pyrimidinone derivatives
GB838315542A GB8315542D0 (en) 1983-06-07 1983-06-07 Pyrimidinone derivatives
GB838327859A GB8327859D0 (en) 1983-10-18 1983-10-18 Pyrimidine derivatives

Publications (2)

Publication Number Publication Date
FI841128A0 FI841128A0 (fi) 1984-03-21
FI841128A7 true FI841128A7 (fi) 1984-09-26

Family

ID=27262023

Family Applications (1)

Application Number Title Priority Date Filing Date
FI841128A FI841128A7 (fi) 1983-03-25 1984-03-21 Pyrimidinderivat, deras framstaellning och deras anvaendning.

Country Status (13)

Country Link
US (3) US4612376A (OSRAM)
EP (1) EP0123402B1 (OSRAM)
KR (1) KR840008333A (OSRAM)
CA (1) CA1256107A (OSRAM)
DE (1) DE3473875D1 (OSRAM)
DK (1) DK160492C (OSRAM)
ES (2) ES8505972A1 (OSRAM)
FI (1) FI841128A7 (OSRAM)
GR (1) GR81758B (OSRAM)
HU (1) HU195195B (OSRAM)
NO (1) NO841168L (OSRAM)
PH (1) PH22022A (OSRAM)
SU (2) SU1349698A3 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US4598149A (en) * 1984-03-02 1986-07-01 Merck & Co., Inc. 3-amino-2-hydroxypropyl of pyrimidin-4-one useful as antihypertensive, cardioprotective, antiarrythmic, and antianginal agents
US4649142A (en) * 1984-06-25 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
US4708958A (en) * 1986-09-24 1987-11-24 G. D. Searle & Co. 6-(imidazolyphenyl)-4-iminopyrimidinones useful as hypotensive agents
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
IT1270122B (it) * 1994-10-04 1997-04-28 Ist Superiore Sanita 6-benzil-4-ossopirimidine sostituite, processo per la loro preparazione e composizioni farmaceutiche che le contengono
WO1997009318A1 (fr) * 1995-09-06 1997-03-13 Kowa Co., Ltd. Derives de la pyrimidine
US6244121B1 (en) * 1998-03-06 2001-06-12 Applied Materials, Inc. Sensor device for non-intrusive diagnosis of a semiconductor processing system
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
BRPI0412689A (pt) 2003-07-14 2006-10-03 Arena Pharm Inc derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
AU2006283211B2 (en) * 2005-08-22 2012-06-21 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
US20100152215A1 (en) * 2007-02-20 2010-06-17 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
AU2008279242A1 (en) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating IRS-1 and AKT
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
EP2462123B1 (en) * 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
JP6632532B2 (ja) * 2014-08-29 2020-01-22 国立大学法人 東京大学 オートタキシン阻害活性を有するピリミジノン誘導体
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US10786503B2 (en) 2017-04-10 2020-09-29 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
EP3801459B1 (en) 2018-06-06 2024-08-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN109053589A (zh) * 2018-09-30 2018-12-21 浙江师范大学 4-亚胺基四氢嘧啶-2-酮类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296371A (OSRAM) * 1969-02-26 1972-11-15
AU1108070A (en) * 1969-03-06 1971-08-12 Imperial Chemical Industries Limited Pyrimidine derivatives
GB1336138A (en) * 1969-12-10 1973-11-07 Ici Ltd Process for the production of pyrimidine derivatives
US3923807A (en) * 1973-09-10 1975-12-02 Takeda Chemical Industries Ltd 6-Aminouracil derivatives
US4208366A (en) * 1978-10-31 1980-06-17 E. I. Du Pont De Nemours And Company Process for preparing a nonwoven web
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent

Also Published As

Publication number Publication date
ES530916A0 (es) 1985-06-16
CA1256107A (en) 1989-06-20
DK166884A (da) 1984-09-26
EP0123402A2 (en) 1984-10-31
DK160492B (da) 1991-03-18
GR81758B (OSRAM) 1984-12-12
HU195195B (en) 1988-04-28
ES8505972A1 (es) 1985-06-16
ES8601922A1 (es) 1985-11-01
SU1436872A3 (ru) 1988-11-07
DK160492C (da) 1991-08-26
US4746664A (en) 1988-05-24
SU1349698A3 (ru) 1987-10-30
ES538190A0 (es) 1985-11-01
KR840008333A (ko) 1984-12-14
US4824851A (en) 1989-04-25
EP0123402A3 (en) 1985-09-18
EP0123402B1 (en) 1988-09-07
US4612376A (en) 1986-09-16
DE3473875D1 (en) 1988-10-13
FI841128A0 (fi) 1984-03-21
NO841168L (no) 1984-09-26
PH22022A (en) 1988-05-13
DK166884D0 (da) 1984-03-23

Similar Documents

Publication Publication Date Title
FI843594A0 (fi) Trihalogenmetylgrupper innehaollande karbonylmetylenheterocykler, foerfarande foer deras framstaellning och ljuskaenslig blandning vilken innehaoller dessa foereningar.
FI842981A7 (fi) Insulinderivatkristallsuspensioner, foerfarande foer deras framstaellning och deras anvaendning.
FI845038A0 (fi) Vattenloeslig, aminerad -1,3-bunden d-glukan och komposition innehaollande densamma.
FI841082L (fi) Kondenserade imidazolfoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner.
FI77939B (fi) Askorbatstoerningsfri komposition, anordning och foerfarande foer bestaemning av peroxidativt aktiva substanser.
FI840748L (fi) Kinolonkarbonsyror, foerfarande foer deras framstaellning och dessa innehaollande antibakteriella aemnen.
FI841128A7 (fi) Pyrimidinderivat, deras framstaellning och deras anvaendning.
FI840653A7 (fi) Imidazo-heterocykliska foereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
FI843856A0 (fi) 1-benzyl-aminoalkyl-pyrrolidinoner och deras syraadditionssalter, foerfarande foer deras framstaellning och laekemedel.
FI842078L (fi) Makroporoesa paerlpolymerisat, foerfarandet foer deras framstaellning och deras anvaendning.
FI840027A7 (fi) Disubstituerade prolinderivat, foerfaranden foer deras framstaellning och deras anvaendning.
FI842459L (fi) Tetrahydropyridazinonderivat, foerfaranden foer deras framstaellning och deras anvaendning.
FI841841A0 (fi) 1-pyrimidinyloxi-3-hetarylalkylamino-2- propanoler, deras framstaellning och anvaendning.
FI842009L (fi) Stenkol-vattenblandningar, vilka innehaoller icke-ioniserbara och anioniska ytaktiva aemnen.
FI844889L (fi) Foernaetade polymerater, foerfarande foer deras framstaellning och deras anvaendning.
FI842104L (fi) Farmaceutiska peptider, framstaellning, bruk och mellanprodukter.
FI830032L (fi) Foerfarande och anordning foer bestaemmande av en oenskad centrallinje foer cylinderlika kroppar, saosom traestockar.
FI842369A7 (fi) Elastomera kopolymerer, deras fram- staellning och anvaendning.
FI840611L (fi) Diagnostiskt aemne, foerfarande foer framstaellning daerav och anvaendning daerav i diagnostiska metoder.
FI840428L (fi) Biologiskt aktivt ketonderivat, framstaellning och anvaendning.
FI841475A7 (fi) Triazinderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
FI842210A0 (fi) Kefalosporinester-derivat, deras framstaellning och anvaendning.
FI841527A7 (fi) Triatsinderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
FI841615A7 (fi) 4-fenyl-tetrahydro-furano-pyridiner, foerfarande foer deras framstaellning och farmaceutiska blandningar.
FI842845A7 (fi) Foerfarande och anordning foer styrning av omkopplarna i en flerfasig pulsvaexelriktare, isynnerhet i en transistorvaexelriktare.

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD.